The newly cleared capability uses AI through the smartSET pulse oximetry sensor platform.
IRVINE, Calif. & RESTON, Va.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a leading medical technology innovator, and Practice Greenhealth, a prominent organization dedicated to advancing sustainability ...
CHICAGO & IRVINE, Calif.--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) and Masimo (Nasdaq: MASI) today announced a joint agreement to integrate Masimo Signal Extraction Technology® (SET®) pulse ...
The Portrait Mobile system’s around-the-clock readings are meant to be an upgrade to traditional in-hospital monitoring methods, which typically check on patients’ vital signs only once every few ...
Masimo Corp. ((MASI)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
The FDA clearance allows the W1 wearable to be sold for both over-the-counter and prescription use—making it the first SpO2-tracking smartwatch to carry both indications in the U.S., per Masimo.
NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results